Taken together, these findings suggest that pairing homogeneously expressed targets (B7-H3, TYRP1) with controllable safety switches (iCas9 + AP1903) and, potentially, regional portal-venous delivery could finally overcome the dual hurdles of safety and tumor heterogeneity, making initial clinical reports feasible within the next few years. Here, CD276 is linked to neoplasm.